Jeena Sikho Lifecare Limited has informed the Exchange regarding ' Jeena Sikho Lifecare Limited has informed the Exchange about Approval of Clinical Trial of Shuddhi Dr. Madhumeh (Diabetes Tablets)'.
JSLL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Jeena Sikho Lifecare has received approval to conduct a clinical trial for its Ayurvedic diabetes product 'Shuddhi Dr. Madhumeh' tablets, registered with the Clinical Trials Registry – India (CTRI/2025/02/080640, dated February 17, 2025). The study is an open-label, single-arm, post-marketing surveillance trial involving just 40 participants over 3 months, conducted at GS Ayurveda Medical College & Hospital in Pilkhuwa, Ghaziabad. Jeena Sikho Lifecare is the primary sponsor, and Dr. Rakhi Mehra is the principal investigator. The trial will assess safety and efficacy by measuring changes in HbA1c, blood counts, and urine parameters. Notably, this is a post-marketing study (product is already in the market), not a new drug approval — DCGI clearance is marked 'Not Applicable.'
This is a small-scale validation study for an already-commercialised Ayurvedic product, so it is unlikely to be a meaningful stock catalyst. Investors should treat it as a routine product credibility exercise rather than a major commercial or regulatory milestone.